UCB Inks Buyback-Option Deal With Wilex For Oncology Lineup
This article was originally published in The Pink Sheet Daily
Executive Summary
Sharing costs and risk could help ease UCB’s recent woes with Cimzia, Neupro.
You may also be interested in...
Deal Watch: Genentech Pays Big For Seragon’s Early Assets
Genentech pays $725 million upfront for San Diego oncology firm Seragon, and Bluebird adds gene-editing and cell-signaling capabilities by acquiring Precision Genomic Engineering. It was a deal-heavy week ahead of the July 4th Holiday.
UCB’s New Strategy Takes SHAPE As GSK Buys Out Emerging Markets
For about $670 million, GSK acquires UCB drugs and infrastructure in several dozen non-BRIC markets.
UCB’s New Strategy Takes SHAPE As GSK Buys Out Emerging Markets
For about $670 million, GSK acquires UCB drugs and infrastructure in several dozen non-BRIC markets.